Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by venture009on Dec 14, 2023 12:03pm
117 Views
Post# 35784641

RE:RE:RE:RE:Idle Evening Thoughts

RE:RE:RE:RE:Idle Evening Thoughts I agree with you regarding Coffey's respect for the shareholder. He has displsyed his contempt over and over, and for that matter most of the other management and BoD has done the same.His promoting a r/s was the worse and then canceling the warrants was another. However, canceling the warrants told the market not to expect any share appreciation soon, which has been the case. Now we are faced with trying to redict future expectations.  Most on this board had predicted that something of significance would happen before the end of 2023. Those hopes are rapidly fading. To complicate things the Business developemnt President appears to have jumbed ship. Why ONC hasn't made some kind of announcement regarding this is troubling. They should have made an announcement within 24 hours of his vacating. Another example of ONC contempt for the retail shareholder. It seems every year at this time we try to second guess the past and predict the future. The results published in 2023 seemed positive but the market has completely ignored these results. and to amplify thid doubt, Coffey recruiting the Anson group emphasized the fact that perhaps we should all temper our expectations, especially because no BP has stepped forward . So 2024, if no BP stepped up within a month , max 2 months, 2024 will be a difficult year because they don't have the financial resources to do much but keep the lights on. In the mean time we await a relase on the Business President, may be that will help provide some clarity but the market reaction in 2023 doesn't provide a lot optimism for 2024. IMO. 
<< Previous
Bullboard Posts
Next >>